Evidence map›Paper›PMID 28332000›Full record

ArticleJournal of neuro-oncology2017

Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival.

Matthew Mason, Catherine Maurice, Mairead G McNamara, Minh Thi Tieu, Zarnie Lwin, Barbara-Ann Millar, Cynthia Menard, Normand Laperriere, Michael Milosevic, Eshetu G Atenafu and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matthew MasonDepartment of Radiation Oncology, University Health Network-Princess Margaret Cancer Centre/University of Toronto, 610 University Ave., Toronto, ON, M5G 2M9, Canada.
Catherine MauriceDepartment of Neurology, University of Toronto, Toronto, ON, M5G 2M9, Canada.
Mairead G McNamaraDepartment of Medical Oncology, University Health Network-Princess Margaret Cancer Centre, Toronto, ON, M5G 2M9, Canada.
Minh Thi TieuDepartment of Radiation Oncology, University Health Network-Princess Margaret Cancer Centre/University of Toronto, 610 University Ave., Toronto, ON, M5G 2M9, Canada.
Zarnie LwinDepartment of Medical Oncology, Royal Brisbane and Women's Hospital & The Prince Charles Hospital UQ School of Medicine, Chermside, QLD, 4032, Australia.
Barbara-Ann MillarDepartment of Radiation Oncology, University Health Network-Princess Margaret Cancer Centre/University of Toronto, 610 University Ave., Toronto, ON, M5G 2M9, Canada.
Cynthia MenardDepartment of Radiation Oncology, University Health Network-Princess Margaret Cancer Centre/University of Toronto, 610 University Ave., Toronto, ON, M5G 2M9, Canada.
Normand LaperriereDepartment of Radiation Oncology, University Health Network-Princess Margaret Cancer Centre/University of Toronto, 610 University Ave., Toronto, ON, M5G 2M9, Canada.
Michael MilosevicDepartment of Radiation Oncology, University Health Network-Princess Margaret Cancer Centre/University of Toronto, 610 University Ave., Toronto, ON, M5G 2M9, Canada.
Eshetu G AtenafuDepartment of Biostatistics, University Health Network-Princess Margaret Cancer Centre/University of Toronto, Toronto, ON, M5G 2M9, Canada.
Warren MasonDepartment of Neurology, University of Toronto, Toronto, ON, M5G 2M9, Canada.
Caroline ChungDepartment of Radiation Oncology, University Health Network-Princess Margaret Cancer Centre/University of Toronto, 610 University Ave., Toronto, ON, M5G 2M9, Canada. caroline.chung.md@gmail.com.ORCID 0000-0002-9662-1519

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated neutrophil-lymphocyte ratio (NLR) may predict worse outcomes in cancer, including glioblastoma (GBM). This study assessed whether change in NLR during focal radiotherapy and concomitant temozolomide (RT-TMZ) provides further prognostic information. This was a retrospective review of patients treated with RT-TMZ for histologically confirmed GBM from January 2004 to September 2010. Variables assessed included age, ECOG performance status (PS), dexamethasone use and extent of surgery. Hematological results were collected at baseline, during and 4 weeks post RT-TMZ. Kaplan-Meier method was used to calculate overall survival (OS). Multivariable analysis (MVA) assessed for joint effect of covariates on OS and Pearson Correlation Coefficients assessed for association between dexamethasone dose and NLR change. With a median age of 55 (range 18-70), 369 patients were included. Median follow up was 15.1 month (range 1.6-134.6). The OS was 66.1% (95% CI 61.2-70.6) and 31.4 (95% CI 26.8-36.1) at 1 and 2 years, respectively. On univariate analysis, both decrease in NLR post RT-TMZ (HR 0.641, p < 0.0001) and baseline NLR < 7.5 (HR 0.628, p < 0.0001) were associated with longer OS. On MVA decrease in NLR (HR 0.727, 95% CI 0.578-0.915), age (HR 1.025, 95% CI 1.012-1.038), baseline neutrophil (<8) (HR 0.689, 95% CI 0.532-0.891), total TMZ cycles (HR 0.89, 95% CI 0.867-0.913) and PS (HR 0.476, 95% CI 0.332-0.683) were independent predictors of OS. These findings suggest that a decrease in NLR during RT-TMZ, accounting for known prognostic factors, is an independent prognostic factor for survival in GBM.

Indexed as

AdolescentAdultAgedBrain NeoplasmsChemoradiotherapyFemaleGlioblastomaHumansKaplan-Meier EstimateLymphocyte CountLymphocytesMaleMiddle AgedNeutrophilsPrognosisRetrospective StudiesGlioblastomaNeutrophil–lymphocyte ratioPrognosisRadiationTemozolomide

Identifiers

PMID28332000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.